Navigation Links
BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
Date:11/2/2009

tatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEX (GM-CSF) has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data so far generated coupled with the relatively benign side effect profile noted to date. Previous clinical trials have enrolled patients with breast cancer, melanoma, head and neck cancer and pancreatic cancer, with indications of clinical activity being observed in each. The Company recently commenced a Phase 3 study in metastatic melanoma following the achievement of an unprecedented proportion of durable complete remissions in a Phase 2 study using OncoVEX (GM-CSF) as a stand alone therapy. An overview of the Phase 2 melanoma results is available on the BioVex website. In September 2009 the Company received approval under the SPA procedure in relation to a second Phase 3 study in head and neck cancer.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch grade manufacturing facility. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

In addition to OncoVEX, the Company has a second development program, ImmunoVEX (HSV2), a vaccine for genital herpes that provides complete protection in animal models of the disease. The vaccine has been authorized to commence clinical testing in the United Kingdom.

For further information, please go to www.biovex.com.

SOURCE BioVex Inc


'/>"/>
SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
2. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
3. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
6. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
7. Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call
8. ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement
9. Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc.
10. Stryker Announces Change in Chairman of the Board of Directors
11. Cardica Announces Fiscal 2010 First Quarter Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
(Date:9/1/2015)... Sept. 1, 2015  Dynatronics Corporation (NASDAQ: ... at the First Annual Ladenburg Thalmann Healthcare Conference ... Kelvyn H. Cullimore, Jr. , Chairman and ... investment representatives on Tuesday, September 29 at 10:30 ... Conference will showcase leading-edge companies in the healthcare ...
(Date:9/1/2015)... -- Dr. Cindy Orser , the Chief Science Officer ... of DigiPath, Inc. (OTCQB: DIGP), was recently interviewed ... consistency in today,s medical cannabis testing industry. In her ... she explained that the state-to-state variations in cannabis laws ... makes standardization impossible. Dr. Orser is ...
Breaking Medicine Technology:Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... China , April 29 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. (NYSE ... pharmaceuticals company in China , today announced,that it has retained CCG ... , , ... to working with CCG to establish more effective and,transparent communications channels with ...
... , April 29 Royal Philips Electronics ( ... provider of integration solutions in healthcare, to deploy the Orion Health Rhapsody® ... , , ... , , ...
Cached Medicine Technology:China Pharma Holdings, Inc. Retains CCG Investor Relations 2China Pharma Holdings, Inc. Retains CCG Investor Relations 3China Pharma Holdings, Inc. Retains CCG Investor Relations 4China Pharma Holdings, Inc. Retains CCG Investor Relations 5Philips and Orion Health Partner to Deliver on Enterprise Interoperability 2Philips and Orion Health Partner to Deliver on Enterprise Interoperability 3Philips and Orion Health Partner to Deliver on Enterprise Interoperability 4
(Date:9/1/2015)... ... 02, 2015 , ... The Journal of Pain Research has published ... ”. , As corresponding author Mr Christopher Malone says “Migraine headache is a painful ... endeavoured to better understand how migraine headaches impact the lives of migraineurs. We asked ...
(Date:9/1/2015)... ... 01, 2015 , ... Stress comes in many different forms ... changes can lead to very serious, life-altering events. Fortunately nature offers a range ... supplement manufacturer MediHerb has coupled therapeutic doses of Rhodiola and Schisandra ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia State ... universities across the country in stemming sexual assaults on their campuses. , The ... a consortium of sexual assault researchers and student affairs professionals responding to calls ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... vacuum that creates negative pressure inside a wound to remove exudates, fluid, and ... treatment devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is ...
(Date:9/1/2015)... PA (PRWEB) , ... September 01, 2015 , ... The ... 18 at The ACE Club and Green Valley Country Club in Lafayette Hill, PA. ... has raised more than $13.5 million for programs and services designed to support patients ...
Breaking Medicine News(10 mins):Health News:Migraine, treatment, comorbidities, and quality of life published by Dove Medical Press 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3
... It prevents many complications of chronic disease, experts ... who strictly control their blood sugar levels also ... disease, British researchers report. , There have been ... reducing blood sugar levels in diabetic patients in ...
... (Pink Sheets: FTER), owner and operator of the "A ... today that the documentary "Intervention," which features this Forterus ... Network at 7 p.m. Eastern and Pacific on Monday, ... people who are seeking a route to redemption from ...
... Gerberding, former Director of the Center for Disease Control and Prevention ... and of CAI International Inc., have been elected to the ... ... Washington, D.C. (Vocus) May 22, 2009 -- Dr. Julie Gerberding, ...
... African American women with late stage breast cancer refused chemotherapy ... July 1, 2009 issue of CANCER , a peer-reviewed ... more efforts are needed to ensure that all women with ... African American women have almost twice the rate of advanced ...
... can be linked to different invasive breast cancer subtypes. ... open access journal Breast Cancer Research , suggests ... are associated with different kinds of tumor. , Marilyn ... a team of researchers who used data from the ...
... Delivery of PMTCTGENEVA, May 21 In a dramatic ... of the International Treatment Preparedness Coalition (ITPC) and AIDS-Free ... members of UNAIDS and WHO to present ITPC,s latest ... Failing Children: HIV, Vertical Transmission and Women,s Health, ...
Cached Medicine News:Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 2Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 3Health News:Julie Gerberding and Hiromitsu Ogawa Join Accordia Board 2Health News:African-American women with advanced breast cancer often forego vital treatment 2Health News:AIDS Treatment Activists Push UNAIDS and WHO to Meet Commitments to Reduce HIV in Women and Newborns 2Health News:AIDS Treatment Activists Push UNAIDS and WHO to Meet Commitments to Reduce HIV in Women and Newborns 3
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
... The Carriazo-Pendular microkeratome is based ... of the cornea during the cut., ... applanated evenly from the beginning of ... ensures that the intraocular pressure does ...
Medicine Products: